Arrowhead Pharmaceuticals, Inc.
$84.91-4.2%YTD+35.1%1Y+280.1%
Mentions · last 7 days
49+11%
Price updated 3d ago·X counts updated 7d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $ARWR, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $ARWR.
Biotechnology
GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.
What this means for $ARWR
Partial — upstream oil & gas exposure ties to commodity price cycle; Arrowhead Pharmaceuticals, Inc.
Top industry ETF
$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-34.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-11.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-35.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-0.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
16.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-55.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
100%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
2.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-1.36$-1.28-6.3%
Q1 2026May 7, 2026$-0.93$-1.09+14.7%
Q4 2025Feb 5, 2026$0.22$0.60-63.3%
Q3 2025Nov 25, 2025$-0.18$-0.11-61.3%
Next earningsTue, Nov 24·consensus EPS $-1.52
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$73.7M-86.4%100%-192%$-0.93$81.9M
Q1 FY26$264.0M+10461.3%100%15.5%$0.22$11.3M
Q4 FY25$256.5M—100%17.2%$-0.17$13.0M
Q3 FY25$27.8M—100%-596%$-1.26$-157.1M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$463.1M$372.9M – $619.9M-$3.13-$3.86 – -$1.8810
FY27$327.0M$119.0M – $579.6M-$4.37-$6.96 – -$2.1010
FY28$645.2M$341.5M – $1.1B-$2.76-$5.05 – $0.718
FY29$922.2M$560.9M – $1.4B-$1.58-$2.75 – -$0.774
FY30$1.8B$1.1B – $2.8B$3.16$1.55 – $5.514
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.86%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+1.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+21.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 122.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.295-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
3New insider — initial holdingsJun 173
AI summary
8-KOfficer or director changeJun 168-K — Item 5.02: Officer or director change
AI summary
8-KShareholder voteMar 208-K — Item 5.07: Shareholder vote
+ 13 other (8 13Gs · 2 earnings 8-Ks · 2 10-Qs · 1 S-8) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe HypertriglyceridemiaArrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe HypertriglyceridemiaArrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology CongressDeutsche Bank AG Invests $12.16 Million in Arrowhead Pharmaceuticals, Inc. $ARWRPeople Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
In themes
Explore the broader themes this ticker is being talked about under.
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 15 · last 7 days